74 related articles for article (PubMed ID: 38640325)
21. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
Husereau D; Drummond M; Augustovski F; de Bekker-Grob E; Briggs AH; Carswell C; Caulley L; Chaiyakunapruk N; Greenberg D; Loder E; Mauskopf J; Mullins CD; Petrou S; Pwu RF; Staniszewska S;
BMJ; 2022 Jan; 376():e067975. PubMed ID: 35017145
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T; Park JW; Finn RS; Cheng AL; Mathurin P; Edeline J; Kudo M; Harding JJ; Merle P; Rosmorduc O; Wyrwicz L; Schott E; Choo SP; Kelley RK; Sieghart W; Assenat E; Zaucha R; Furuse J; Abou-Alfa GK; El-Khoueiry AB; Melero I; Begic D; Chen G; Neely J; Wisniewski T; Tschaika M; Sangro B
Lancet Oncol; 2022 Jan; 23(1):77-90. PubMed ID: 34914889
[TBL] [Abstract][Full Text] [Related]
23. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Ding D; Hu H; Li S; Zhu Y; Shi Y; Liao M; Liu J; Tian X; Liu A; Huang J
J Natl Compr Canc Netw; 2021 Aug; 19(10):1141-1147. PubMed ID: 34348237
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
[TBL] [Abstract][Full Text] [Related]
26. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US.
Wang Y; Rui M; Yang L; Wang X; Shang Y; Ma A; Li H
Front Public Health; 2021; 9():650392. PubMed ID: 33889559
[No Abstract] [Full Text] [Related]
27. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes.
Bebber CM; Thomas ES; Stroh J; Chen Z; Androulidaki A; Schmitt A; Höhne MN; Stüker L; de Pádua Alves C; Khonsari A; Dammert MA; Parmaksiz F; Tumbrink HL; Beleggia F; Sos ML; Riemer J; George J; Brodesser S; Thomas RK; Reinhardt HC; von Karstedt S
Nat Commun; 2021 Apr; 12(1):2048. PubMed ID: 33824345
[TBL] [Abstract][Full Text] [Related]
28. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H
Curr Oncol; 2021 Feb; 28(2):1094-1113. PubMed ID: 33673470
[TBL] [Abstract][Full Text] [Related]
29. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
[TBL] [Abstract][Full Text] [Related]
30. Small-cell lung cancer.
Rudin CM; Brambilla E; Faivre-Finn C; Sage J
Nat Rev Dis Primers; 2021 Jan; 7(1):3. PubMed ID: 33446664
[TBL] [Abstract][Full Text] [Related]
31. First-Line Durvalumab Plus Platinum-Etoposide
Zhang L; Hang Y; Liu M; Li N; Cai H
Front Oncol; 2020; 10():602185. PubMed ID: 33344252
[TBL] [Abstract][Full Text] [Related]
32. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in Small Cell Lung Cancer.
Esposito G; Palumbo G; Carillio G; Manzo A; Montanino A; Sforza V; Costanzo R; Sandomenico C; La Manna C; Martucci N; La Rocca A; De Luca G; Piccirillo MC; De Cecio R; Botti G; Totaro G; Muto P; Picone C; Normanno N; Morabito A
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899891
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology of lung cancer and lung cancer screening programs in China and the United States.
Yang D; Liu Y; Bai C; Wang X; Powell CA
Cancer Lett; 2020 Jan; 468():82-87. PubMed ID: 31600530
[TBL] [Abstract][Full Text] [Related]
36. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q
Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
[TBL] [Abstract][Full Text] [Related]
39. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Hellmann MD; Callahan MK; Awad MM; Calvo E; Ascierto PA; Atmaca A; Rizvi NA; Hirsch FR; Selvaggi G; Szustakowski JD; Sasson A; Golhar R; Vitazka P; Chang H; Geese WJ; Antonia SJ
Cancer Cell; 2019 Feb; 35(2):329. PubMed ID: 30753829
[No Abstract] [Full Text] [Related]
40. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Ejzykowicz F; Burke T
Curr Med Res Opin; 2019 Jul; 35(7):1241-1256. PubMed ID: 30649973
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]